Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 12, 2025Open Access

This Meta-Analysis Evaluates the Optimal Timing for Initiating and Discontinuing Eltrombopag for Aplastic Anemia

View Full Paper
Ask AI
Bookmark
Share

Authors

STShuai TanMSMingyue ShangYGYue Leon Guo

Discussion

Loading...

Member takes

Overview

Meta-analysis demonstrates improved hematological outcomes with early Eltrombopag use and IST in aplastic anemia.

Key Points

  • Eltrombopag improves hematological improvement rates significantly in aplastic anemia compared to IST alone.
  • At 3 months, the odds ratio for response in the EPAG+IST group was 2.13, indicating better efficacy.
  • Analysis included 21 studies with 2,239 patients, assessing different age groups and treatment timelines.
  • Early initiation of Eltrombopag shows no significant risks while enhancing treatment outcomes over a 3-6 month period.

Cite This Study

Tan et al. (2025) studied this question.

synapsesocial.com/papers/68ebc91af2c3e4d8d926e493https://doi.org/10.21203/rs.3.rs-7631623/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Initiating Eltrombopag (EPAG) Early for aplastic Anemia (AA) may Lead to greater clinical benefits: A systematic review and meta-analysis2025
  2. 2A Multicenter, Retrospective Study Comparing Immunosuppressive Therapy Combined with Eltrombopag to Immunosuppressive Therapy Alone as Front-Line Treatment for Pediatric Severe Aplastic Anemia.2025 · 2 citations
  3. 3Outcomes of eltrombopag combined with immunosuppressive therapy in adults with severe aplastic anemia: A large, propensity-matched retrospective analysis2025
  4. 4Long-term outcomes of intensive immunosuppressive therapy combined with eltrombopag in patients with severe aplastic anemia2025
  5. 5Efficacy and influencing factors of immunosuppressive therapy combined with or without eltrombopag in children with severe aplastic anemia2025